Personalizing Therapies with Ex Vivo Pharmacological

Total Page:16

File Type:pdf, Size:1020Kb

Personalizing Therapies with Ex Vivo Pharmacological PERSONALIZING THERAPIES WITH EX VIVO PHARMACOLOGICAL RESPONSES MAY UNCOVER THE DIFFERENCES BETWEEN IDA-DNR-MIT AMONG EUROPEAN AML PROTOCOLS Pau Montesinos1, David Martínez 1, Raimundo García2, Jaime Pérez de Oteyza3 , Pascual Fernández4, Josefina Serrano5 , Ángeles Fernández6, Pilar Herrrera7 , Arancha Alonso8, Ataulfo González9, Concepción Bethancourt10, Esperanza Lavilla11, Juan Antonio Vera12, Begoña Navas13, Gabriela Rodríguez14, Juan Antonio López15, Santiago Jiménez Bravo de la Laguna16, Adriana Simiele17, Bernardo González18, Jose Angel Hernández Rivas19, Raúl Córdoba20, Consolación Rayón21, Carmen Burgaleta22, Jorge Sierra23, Iñaki F. Trocóniz24, Ignacio Ortega25, Andrew G. Bosanquet26, Daniel Primo27, Pilar Hernández-Campo27, Julian Gorrochategui27, Jose L. Rojas27, Teresa A. Bennett27 , Belén Liébana27, Rocío López27, Joan Ballesteros Nobell27 , Federico Moscardó1, Miguel Ángel Sanz1, Joaquín Martínez López28 1Haematology, Hospital Universitari i politecnic La Fe, Valencia, Spain, 2Haematology, Hospital Universitario General de Castellón, Castellón, Spain, 3Haematology, Hospital de Madrid Norte Sanchinarro, Madrid, Spain, 4Haematology, Hospital General Universitario de Alicante, Alicante, Spain, 5Haematology, Hospital Universitario Reina Sofía, Córdoba, Spain, 6Haematology, Complejo Hospitalario Xeral Cíes de Vigo, Vigo, Spain, 7Haematology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 8Haematology, Hospital Quirón Madrid, Spain, 9Haematology, Hospital Clínico San Carlos, Madrid, Spain, 10Hospital Regional Universitario Carlos Haya, Málaga, Spain, 11Hospital Universitario Lucus Augusti, Lugo, Spain, 12Hospital Universitario Virgen de la Macarena, Sevilla, Spain, 13Hospital Moncloa, Madrid, Spain, 14Haematology, Hospital Universitario Gregorio Marañón, Madrid, Spain, 15Haematology, Complejo Hospitalario de Jaén, Jaén, Spain, 16Haematology, Hospital Universitario de Gran Canaria Doctor Negrín, Gran Canaria, Spain, 17Haematology, Hospital Povisa, Vigo, Spain, 18Haematology, Hospital Universitario de Canarias, Tenerife, Spain, 19Haematology, Hospital Universitario Infanta Leonor, Madrid, Spain, 20Haematology, Hospital Universitario Infanta Sofía, Madrid, Spain, 21Haematology, Hospital Universitario Central de Asturias, Oviedo, Spain, 22Haematology, Hospital Universitario Príncipe de Asturias, Madrid, Spain, 23Haematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 24Universidad de Navarra, Pamplona, Spain, 25Universidad del País Vasco, Bilbao, Spain, 26Bath Cancer Research, Bath, England, 27Vivia Biotech, Madrid, Spain, 28Haematology, Hospital Universitario Doce de Octubre, Madrid, Spain ABSTRACT METHODS ExviTech© Platform PLATE SETUP WHOLE SAMPLE vs. ISOLATED LYMPHOCYTES Background and objectives: Protocols for acute myeloid leukemia (AML) 1st line patients are centered on the combination of Cytarabine and an anthracycline; Idarubicin (IDA), Daunorubicin (DNR),or Mitoxantrone (MIT).Patients may be treated with IDA, DNR, or MIT Robotic Sample Automated FCM BeckmanCoulter Cyan Proprietary Activity Base Bioinformatics CYT-IDA Preparation Based Screening Flow Cytometer Analysis Results + Clinical Info A IDA-DAU-MIT depending on the country of residence, because multiple clinical trials have not found significant differences among them. A new Software Eight different concentrations of each drug or A. Dose-response curves for D Personalized Medicine (PM) test developed by Vivia Biotech based on pharmacological responses in patient samples(ex vivo)is uncovering drug combination is run for the used treatment IDA and CYT in isolated individual responses to these treatments. Our objective is to explore whether a significant % of individual patients may respond differently protocols. The max concentration used is listed leukocytes and whole sample. to IDA vs DNR vs MIT treatments, in spite that of their “on average” similar response shown by clinical trials. Data, from sample 6 below, Patients and Methods: Multicenter, prospective, non-interventional study of the PETHEMA group for treatment of AML. Bone Marrow 1 2 3 4 5 6 7 8 9 10 11 12 A displays a log difference in DMSO DMSO 0.47% (BM) samples were collected at diagnosis for 160 AML patients. Samples were incubated for 48 hours in 96well plates, each well B DMSO 0.47% MITOXANTRONE 7µM the EC50s for IDA, but equal C IDARUBICIN containing different drugs or drug combinations, each at 8 different concentrations, enabling calculation of dose response curves for each 3µM results for CYT. B. The EC50 1.5µM D DAUNORUBICIN single drug (CYT, IDA, DNR, MIT) and combination used in treatments(CYT-IDA, CYT-DNR, CYT-MIT). Drug response was evaluated as (y-axis) of the whole sample E CYT + IDA depletion of AML malignant cells in each well after 48 hours incubations. Annexin V-FITC was used to quantify the ability of the drugs to E F CYT + DNR and the isolated leukocyte B induce apoptosis. Malignant cells were identified with monoclonal antibodies and light scatter properties. 1)We use the whole bone G CYT + MIT Screening Setup and Workflow fraction from 9 patient H marrow sample, retaining the erythrocyte population and serum proteins, during the entire incubation period; and after 48h leukocytes DAY 1 samples with CYT. C. EC50 of are isolated prior to evaluation by flow cytometry. 2)We have pioneered development of a proprietary automated flow cytometry platform PB or BM DAY 3 the same samples to IDA. called ExviTech. 3)Pharmacological responses are calculated using pharmacokinetic population models. Analysis and Import Data Analysis: performed using the into ActivityBase population approach using NONMEM 7.2.: Results: Figure 3 shows dose responses for IDA (blue), DNR (red) and MIT (green) in 125AML patient samples. Although their average Split sample REPORT D-F. Dose response curves for population PD modelling of the ex vivo curves (Figure 2) are similar, the inter-patient variability of either drug is quite large. We hypothesized that some patients could show very GENERATED IDA (D) DAU (E) MIT (F) for 2 F response vs concentration data in differential sensitivities to these drugs, as illustrated in Figure 4 (panel A) where a patient sample is resistant to IDA (right shifted dose C samples (red, blue), in whole monotherapy (fig.2), establishing for each response curve) but sensitive to DNR (left shifted dose response curve). To identify these cases, Figure 5 panel A shows a comparison of sample (continuous line) and patient the 95% prediction intervals (PI) of the potency IDA vs DNR. Potency is represented by their EC50 (concentration that kills 50% of the cells). Most dots tend to line up, but red Sample Validation/ isolated leukocytes (dotted Cell Count Apoptotic the isobologram from each individual dots represent patient samples with a difference in potency between these drugs >30%. Repeating this exercise for IDA-MIT and DNR-MIT lines). Blue sample shows Plated Analysis with: parameter (fig.4) computation of the (panels B and C) to cover all alternatives among the 3 anthracyclines identifies 40% of patients samples with >30% different potency Annexin V Anti-CD45 small difference DAU vs large Drugs combination index using raw data descriptors among IDA-DNR-MIT. Repeating this exercise with the combination treatments CYT-IDA, CYT-DNR, CYT-MIT (Figure 6) increases to 58% the Drug-Sample Plates Annexin V Anti-CD14 difference IDA & MIT. Red 48H Anti-CD34 Anti-CD64 Live from combination experiments. Chou and population of patients whose samples have a differential sensitivity to these anthracyclines. A fraction of this 65% of patients may benefit Anti-CD117 Anti-CD13 sample all more similar. in if treatment selection among these 3 treatments were to be aided by this ex vivo testing sensitivities. To identify which fraction would Anti-HLA-DR Anti-CD11b Talalay. 2010. Cancer Research 70: 440-446. benefit we would need a trial specifically designed. Figure 1. Chemosensitivity test Figure 3. Inter-patient Figure 4. Examples of differential Figure 5. Overall statistical Figure 6. Overall statistical Figure 7. Drugs interaction in combination treatments by dose-response modeling analysis variability individual behavior differences among drugs differences among combinations Potency ranking based on EC50 Patient 1 A A 18/106 (16.7%) 40% of patients showed significant IDA differences among potency of three DAU Sensitive Resistant drugs. Surv_Idx (%) Surv_Idx Surv_Idx (%) Surv_Idx Surv_Idx (%) Surv_Idx IDARUBICINE DAUNORUBICIN 58% of patients showing any difference in Patient 2 26/106 (24.5%) B B synergy measurements among the three IDA combinations MIT Shift of dose-response curves to the left (sensitive) or right Figure 7. Inter-patient variability on drug interaction Sensitive (resistant) indicates differences of drug potency exvivo. measurement Resistant Surv_Idx (%) Surv_Idx IDARUBICINE Figure 2. Similar sensitivity IDA DAU MIT (%) Surv_Idx MITOXANTRONE Patient 3 C 24/104 (23.1%) C More than 65% of patients show DAU MIT Sensitive differences either on drug potency or Resistant synergy measurements among Surv_Idx (%) Surv_Idx (%) Surv_Idx Surv_Idx (%) Surv_Idx DAUNORUBICIN CYT-IDA, CYT-DAU, CYT-MIT. MITOXANTRONE IDA Each curve corresponds to the average exvivo effect of Wide Inter-patient variability shown on individual dose-response Examples show how inter-patient variability may result in one Red dots for patients with a response exvivo showing Red dots for patients and combinations indexes showing Box-plots showing population distribution of measured combination index
Recommended publications
  • Suardiaz Groupgroup P
    SUARDIAZSUARDIAZ GROUPGROUP SUARDÍAZ GROUP MAY 2010 SUARDIAZ GROUP - ACTIVITIES GRUPO LOGISTICO SUARDIAZ FLOTA SUARDIAZ PECOVA, Rail Transport LOGISTICA SUARDIAZ FLOTA SUARDIAZ, ROAD TRANSPORT RORO SERVICE SSMB BUNKER SUPPLIES MARITIME AGENCIES GRIMALDI SUARDIAZ INLAND TERMINALS SSS SERVICE STEVEDORING PORTS TERMINALS and and OTHERS STEVEDORING SUARDIAZ GROUP • Suardiaz has been operating for over a century. The head office is located in Madrid, and it renders services throughout Spain and Europe through its network of Delegations and Agencies. • We have own offices all around Spain, 14 offices, main ports, Bilbao, Santander, Gijon, Vigo, Barcelona, Tarragona, Valencia, Sevilla, Cadiz, Algeciras, Tenerife, Las Palmas GC, Madrid, Toledo. • The Suardiaz Group is one of Europe’s most important transport companies in terms of tradition and experience in the maritime logistics and rolling cargo sector. SUARDIAZ GROUP • Our organisational structure allows it to offer clients, integrated logistics and cargo transport services that meet current market demand while constantly making sure to strictly comply with quality and safety standards. Multimode transport (sea, land, air, and rail) Ship Owner Ship Agent Forwarding Chartering Port Operations Storage, deposits, and handling Customs agency Bunkering • In the past few years, the Company has been developing a diversification plan. As a result, new activities have been taken up such as bunkering and transporting crude oil. • Member of the main associations in the transport and logistic market as WWSA, FETEIA, IATA, BIMCO, etc… • Certified by LR ISO 9001. SUARDIAZ GROUP FLOTA SUARDIAZ SUARDIAZ GROUP • Flota Suardiaz is one of Europe’s most experienced and traditional shipping companies when it comes to logistics, transporting vehicles and rolling cargo by sea.
    [Show full text]
  • CNMV Markets Directorate General C/ Edison Núm. 4 28006 Madrid
    CNMV Markets Directorate General C/ Edison núm. 4 28006 Madrid Vigo, June 26, 2019 In accordance with Article 17 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and Article 226 of the recast Spanish Securities Market Act (Ley del Mercado de Valores), the following RELEVANT EVENT is hereby reported: With regard to the regulatory announcements published on 28 January 2019 and 23 May 2019, with submission receipt reference numbers 274,204 and 278,505 respectively, relating to the process of the sale by Pharma Mar, S.A. (“Pharma Mar” or the “Company”) of its subsidiary Zelnova Zeltia, S.A. (“Zelnova”), which includes the sale of the Italian subsidiary Copyr, S.p.A., the Company announces that at the adjourned general meeting of the Company’s shareholders held today in Vigo (Pontevedra), the shareholders authorised the sale of all the shares in Zelnova for a total price of €33,417,000, on the same terms as approved by Pharma Mar’s board on 23 May 2019, to the companies Allentia Invest, S.L. and Safoles, S.A. (together, the “Purchaser”), companies directly and indirectly owned by, among others, Mr Pedro Fernández Puentes, a director of Pharma Mar, and persons connected to him. The shareholders’ authorisation was to comply with Article 230 of the Spanish Companies Act (Ley de Sociedades de Capital), with regard to shareholders’ dispensation from the prohibition on directors’ carrying out transactions with the Company, and to the extent applicable Article 160f of the Spanish Companies Act, as regards shareholders’ approval for the sale of assets considered essential.
    [Show full text]
  • Language and Culture Courses Masters
    LANGUAGE AND CULTURE COURSES UNIVERSIDAD DE SALAMANCA (Salamanca) UNIVERSIDAD DE SALAMANCA (Salamanca) UNIVERIDAD DE ALCALÁ (Madrid) Varieties of Spanish as a Heritage Language (Level Master’s degree in Spanish Language and Culture A world to discover in Spanish language. A world for B2) (C1) reviving in Spanish language (C1) Dates: July 1-21, 2020 Dates: Part I: June 29 – July 31, 2020 Dates: July 6-24, 2020 [email protected] Part II: Summer 2021 [email protected] Price:1,750€ [email protected] Price: 1,700€ Price: 2,479€ per year UNIVERSIDAD DE SANTIAGO DE COMPOSTELA UNIVERSIDAD DE ALICANTE (ALICANTE) (Santiago de Compostela) ELIGIBLE PARTICIPANTS Teaching Spanish for social justice and critical Language and Culture Course. The Way of Saint citizenship (B2) James (B2) - K-12 teachers of Spanish and Community Dates: July 6-24, 2020 Dates: July 6-24, 2020 College teachers. [email protected] [email protected] - Teachers of other subjects. Price: 1,700€ Price: 1,700€ - School Administrators and other professionals. UNIVERSIDAD DE VIGO (Vigo) UNIVERSIDAD DE CASTILLA LA MANCHA LENGTH Teaching and learning Spanish language and culture (Toledo) (B1+) Spanish Language and Culture - COURSES: 60 hours during three weeks. Dates: July 6-24, 2020 Dates: June 22-July 10, 2020 - MASTERS: 500 hours split into two summer [email protected] [email protected] period. Price: 2,150€ Price: 1,700€ GRADUATE CREDITS UNIVERSIDAD DE DEUSTO-BILBAO (Bilbao) Experience Spanish Language and Culture: New MASTERS Three credits every 60 training hour, recognized Resources for the classroom (B1+) at some U.S. Universities. Dates: July 6-24, 2020 Three-year teaching experience [email protected] ADDITIONAL INFORMATION Price: 1,700€ UNIVERSIDAD DE ALCALÁ (Alcalá de Henares, Madrid) Registration: from November 25, 2019 to March UNIVERSIDAD DE GRANADA (Granada) University Master’s degree in teaching of Spanish 27, 2020.
    [Show full text]
  • Grupo Suardiaz Marítimo Logística Multimodal Almacenes Transporte
    Grupo Suardiaz Marítimo Logística Multimodal Transporte Terrestre Almacenes Historia Más de un siglo de experiencia empresarial +70 años en el sector logístico Soluciones Marítimo Logísticas Multimodales 1 Armador y Operador de Líneas Marítimas Carretera 2 Consignatarios y Representantes de Líneas 3 Operador de Transporte Terrestre 4 “Chartering” 5 Operaciones portuarias Ferrocarril 6 Carga de Proyectos 7 Almacenaje: depósito y manipulación 8 Agencia de Aduanas 9 “Bunkering” y transporte de Petróleo Aéreo 10 Terminales Ferroviarias Nantes- Nuestra Red St.Nazaire Empleados Gijón Santander Francia Avilés Bilbao 600 La Coruña Vigo México Marseille Barcelona Tarragona Madrid Colombia Sagunto Valencia Perú Sevilla Alicante Bolivia Huelva Cartagena Argel Cádiz Motril Tanger Algeciras Casablanca Las Palmas Marruecos Argelia OFICINAS Tenerife ALMACENES Greenock Líneas Grimsby Dublin Liverpool Emden Bristol Sheerness Southampton Zeebrugge Marítimas Le Havre St. Nazaire Savona Santander Marseille Bilbao Vigo Livorno Barcelona Tarragona Sagunto Valencia Málaga Algeciras Alger Tanger Mostaganem Casablanca Tenerife Las Palmas Flota Nombre Tipología Capacidad* GT GALICIA Ro/Ro 50 SR / 1200 coches 16.361 SUAR VIGO Ro/Ro 105 SR / 1200 coches 16.361 BOUZAS Ro/Ro 100 SR / 1200 coches 15.224 TENERIFE CAR Ro/Ro 45 SR / 1200 coches 13.112 GRAN CANARIA CAR Ro/Ro 50 SR / 950 coches 9.600 LA SURPRISE Ro/Ro 100 SR / 1200 coches 15.224 L'AUDACE Ro/Ro 100 SR / 1200 coches 15.224 IVÁN Ro/Ro 70 SR / 750 coches 8.191 VERONA Ro/Ro 155 SR / 3500 coches 37.237 CAP CAMARAT Ro/Ro 25 SR / 70 coches 7.095 GREENOIL Bunkering Tanker 4.500 m3 2.743 BUNKER BREEZE Bunkering Tanker 5.000 m3 3.500 ENDEAVOR Portacontenedor - 7.642 * Capacidad real aproximada, no estrictamente ajustada al valor DWT Líneas Marítimas Greenock Grimsby Dublin Liverpool Emden Bristol Línea Atlántica Sheerness Southampton Zeebrugge Le Havre FRECUENCIA: • Semanal: 1.200 coches o 50 SR St.
    [Show full text]
  • Los Robos En Los Hogares Gallegos Los Robos En Los Hogares: Galicia
    Los robos en los hogares gallegos Los robos en los hogares: Galicia Los datos e informaciones contenidos en este informe son propiedad de UNESPA. El propietario cede su uso libre por parte de las entidades aseguradoras miembros de la Asociación, al Instituto Atlántico del Seguro y su Fundación, así como los medios de comunicación. Cualquier otro agente que desee reproducir la totalidad o parte de la información aquí contenida debe para ello de contar con la autorización expresa del propietario. 1 Índice INTRODUCCIÓN DEL ESTUDIO 4 NÚMERO DE ROBOS EN LOS HOGARES GALLEGOS 5 ESTACIONALIDAD DE LOS ROBOS 6 DISTRIBUCIÓN GEOGRÁFICA DE LOS ROBOS 9 EL DATO IMPORTANTE: LA FRECUENCIA 10 GRAVEDAD DE LOS ROBOS: CUÁNTO SE LLEVAN 12 GEOGRAFÍA DE LOS ROBOS POR PROVINCIAS 15 A CORUÑA 15 LUGO 18 OURENSE 20 PONTEVEDRA 22 TRES CIUDADES DE GALICIA: VIGO, A CORUÑA Y SANTIAGO DE COMPOSTELA 25 COMPOSICIÓN DE LAS VIVIENDAS ASEGURADAS Y LOS ROBOS 25 DIFERENCIAS EN LA PROBABILIDAD DE SUFRIR UN ROBO 27 CUÁNTO SE LLEVAN 29 Índice de gráficos ILUSTRACIÓN 1: DISTRIBUCIÓN PROVINCIAL DE LAS VIVIENDAS GALLEGAS Y LOS ROBOS SUFRIDOS POR ÉSTAS. 6 ILUSTRACIÓN 2: ESTACIONALIDAD DE LOS ROBOS EN GALICIA. MESES. 8 ILUSTRACIÓN 3: ESTACIONALIDAD DE LOS ROBOS EN GALICIA: DÍAS DE LA SEMANA. 8 ILUSTRACIÓN 4: 25 POBLACIONES CON MAYOR PROBABILIDAD DE ROBO EN GALICIA. 11 ILUSTRACIÓN 5: MEDIANAS DE COSTE EN LAS CUATRO PROVINCIAS GALLEGAS. 13 ILUSTRACIÓN 6: COMPOSICIÓN DE VIVIENDAS Y ROBOS EN LA CIUDAD DE VIGO. 26 ILUSTRACIÓN 7: COMPOSICIÓN DE VIVIENDAS Y ROBOS EN LA CIUDAD DE SANTIAGO DE COMPOSTELA.
    [Show full text]
  • Memoria Anual 2017 INSTITUTO FRANKLIN-UAH ÍNDICE
    Memoria Anual 2017 INSTITUTO FRANKLIN-UAH ÍNDICE 1. Informe de resultados 9 2. Introducción 13 3. Organización 17 3.1. Consejo Académico 18 3.2. Consejo Asesor 26 3.3. Personal del Instituto 32 4. Investigación 41 4.1. Ayudas a jóvenes investigadores 42 4.1.1. Margaret Fuller 43 4.1.2. Washington Irving 44 4.2. Ayuda formativa para médicos residentes 45 4.3. Ayudas de estudio y lectorado 46 4.4. Investigadores visitantes 47 4.5. Convocatorias para el próximo año 48 4.5.1 Bolsas de Viaje Benjamin Franklin 48 4.5.2. Ayudas de iniciación a la investigación 48 4.5.3. Ayuda Nebrija Creadores 49 5. Grupos de investigación y proyectos en curso 51 5.1. Área de Estudios Norteamericanos 53 5.1.1. Modelos de simulación del cambio climático y su 53 influencia sobre la vegetación potencial en la cuenca del Pacífico norteamericano, I: Modelización bioclimática 5.2. Área de Relaciones Transatlánticas 55 5.2.1. Diccionario enciclopédico sobre la presencia española 55 en el territorio de los actuales Estados Unidos (1512-1821) 5.2.2. Discursos legitimadores de la conquista y la 56 colonización de América al norte y al sur del continente 5.2.3. Influencia de Estados Unidos en el desarrollo del 57 radar en España 5.3. Área de Estudios Comparados 58 5.3.1. Humanidades Ambientales “Relatos para el cambio” 58 5.3.2. Liderazgo femenino: mujer y poder 60 6. Programas académicos 61 6.1. Programas de Estudios Norteamericanos 62 6.1.1. Doctorado 62 6.1.2.
    [Show full text]
  • CARLA ANDRADE 1983 Born Vigo
    CARLA ANDRADE 1983 Born Vigo, Spain Lives and works in Madrid, Spain · Currently studying Philosophy. Madrid University, Spain. · (2001/06) Bachelor in Audiovisual Communication. Salamanca University, Spain. WORKSHOPS · Bernard Plossu: Landscape Photography. 2011. CDAN, Huesca, Spain. · Vari Caramés: "Photography: Emotional Oasis". 2011. Braga, Portugal. COURSES · 2010. W&B Photo developing. La Casa Encendida, Madrid. Spain. · 2009. Documentary Photography in Blank Paper Photography School. Madrid, Spain. ARTIST RESIDENCIES · ARNA. 2012. Harlösa, Sweden. · Herhúsi!. 2012. Siglufjör!ur, Iceland. SOLO EXHIBITIONS 2012 - Eurostars I-Hotel , curated by Abigail López Enrech. Madrid, Spain. 2011 - PA-TA-TA International Photography Festival, curated by Cecilio Puertas. Granada, Spain. GROUP EXHIBITIONS (Upcoming in 2012) - October: NYBA: New York Biennale Art 2012 – 2013. Curated by Pietro Franesi. Javits Center, New York. - October. Open Studio: "The empty space", curated by María López Velasco. Madrid. - November: Jeune Creation 2012. Centquatre, Paris. 2012 - Photofluxo: 3o Winter Photography Festival. ArtEstação. "Arte na Rua". Rio Grande, Brazil. - Young Award Visual Arts UCM 2011. c arte c. Museo del Traje. Madrid, Spain. S A R A H B E L D E N F I N E A R T SAN JUAN DE LA CUESTA 1 4A 28017 MADRID, SPAIN TEL +34 633 170 463 / [email protected] - “Convergencias” Alliance Française Gallery of Madrid, PHotoEspaña 2012. - Galerie Huit. (Screening Installation), curated by Vanja Karas. Les Rencontres d’Arles 2012. France. - Arna Fågelriket, Härlosa, Sweden. - Snap! curated by Picturalis. Petit Bain, Paris. - Nord Art , curated by Wolfgang Gramm. Kunstwerk Carlshütte, Büdelsdorf, Germany. - Fac Peregrina, curated by María Marco. Santiago de Compostela, Spain. - Young Award Visual Arts UCM 2011.
    [Show full text]
  • Geological Antecedents of the Rias Baixas (Galicia, Northwest Iberian Peninsula)
    Journal of Marine Systems 54 (2005) 195–207 www.elsevier.com/locate/jmarsys Geological antecedents of the Rias Baixas (Galicia, northwest Iberian Peninsula) G. Me´ndez*, F. Vilas Grupo de Geologı´a Marina, EX1, de la Universidad de Vigo, Spain Departamento de Geociencias Marinas y Ordenacio´n del Territorio, Universidad de Vigo, 36200 Vigo, Spain Received 19 March 2003; accepted 1 July 2004 Available online 7 October 2004 Abstract The present paper reviews the current state of knowledge regarding the geology of the Rias Baixas (Galicia, northwest Iberian Peninsula), focusing specifically on characterisation, geometry, and evolution of the sedimentary bodies; physical and geological description; drainage patterns; and advances in palaeoceanography and palaeoecology. D 2004 Elsevier B.V. All rights reserved. Keywords: Rias; Galicia; Coast; Geology 1. Introduction date. However, the scientific discourse then began to question whether the Galician rias, given their variety The current state of knowledge regarding the of origins, should be truly considered rias at all. In geology of the Rias Baixas, in the northwestern recent years, research has generally focused on Spanish region of Galicia, is a consequence of an determining their Quaternary evolution, establishing extensive and fruitful research process, with roots links with global processes and characterising the based on Von Richthofen’s proposal (1886) to use the local processes. Moreover, a major line of debate has term ria to designate a type of coastline characterised centered on characterising the so-called Rias Coast, by the existence of a valley occupied by the sea, and establishing a clear distinction between the geological taking as its prototype the Galician rias.
    [Show full text]
  • Service & Sales
    NAVIGATION | COMMUNICATION | SAFETY | SATCOM SOLUTIONS GMDSS AND VDR / SVDR SURVeys | WORLDWIDE SERVICE ARRANGEMENTS Service & Sales MARKET LEADERS SPAIN, GIBRALTAR, POrtUGAL, Malta, MOROCCO, panaMA & THE NETHERLANDS Office Network Tailored Global Solutions AAGE HEMPEL is a well established company in the maritime market ROTTERDAM specialized in the supply, installation, commissioning and service of HARLINGEN TERNEUZEN Navigation, Communication, safety and other maritime equipments as well as a Satcom solutions provider. WOrldwIDE COVeraGE AAGE HEMPEL delivers worldwide service through our own offices LISBON ALGECIRAS (HEAD OFFICE) and our global service network of certified partners wherever you sail. CADIZ Aage Hempel is committed to fulfill our customers’ requests as quickly, HUELVA efficiently and effectively as possible.O ur offices all around Spain, Portugal, Morocco, Malta, The Netherlands and Panama enable us to CARTAGENA provide 24/7 service and support to our customers. PALMA DE MALLORCA VALENCIA TARRAGONA BARCELONA BILBAO SANTANDER OUR SPECIALITIES ARE NAVIGATION, COMMUNICATION, IT GIJON NETWORKS, SATCOM SOLUTIONS, GMDSS / VDR-SVDR SURVEYS A CORUNA AND WORLDWIDE SERVICE ARRANGEMENTS. VIGO Canary Islands LAS PALMAS Dedicated to provide our customers with: • Quality service and repair. • Competitively priced equipment & installation. CASABLANCA • Excellent customer service. • S.B.M Contracts. • International Service Arrangements. AAGE HEMPEL ACCREDITATIONS IN OUR MARKET: • Over 10.000 services annually. • Very high First Time
    [Show full text]
  • Sex-Related Impact on Clinical Outcome of Everolimus-Eluting Vs
    Document downloaded from http://www.elsevier.es, day 30/09/2021. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. REVISTA ESPAÑOLA DE CARDIOLOGÍA Supplementary material _____________________________________________________________________ Sex-related Impact on Clinical Outcome of Everolimus-eluting vs. Bare-metal Stents in ST-segment Myocardial Infarction. Insights From the EXAMINATION Trial Ander Regueiro,a Diego Fernández-Rodríguez,a Salvatore Brugaletta,a Victoria Martín-Yuste,a Monica Masotti,a Xavier Freixa,a Ángel Cequier,b Andrés Íñiguez,c Patrick W. Serruys,d and Manel Sabaté,a,* on behalf of the EXAMINATION Trial ◊ Investigators aServicio de Cardiología, Hospital Clínic, IDIBAPS, Barcelona, Spain bÁrea de Enfermedades del Corazón, Hospital Universitario de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain cServicio de Cardiología, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain dThoraxcenter, Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands ___________________________________________________________________________ Document downloaded from http://www.elsevier.es, day 30/09/2021. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. REVISTA ESPAÑOLA DE CARDIOLOGÍA SUPPLEMENTARY MATERIAL Data Analysis Interaction Assessment To test for interaction, we included an interaction term between treatment Group (EES vs BMS) and sex (Male vs Female) in the Cox model for each end point. If the P value of the interaction term was < .05, effect modification was considered to be present, and the interaction term was included as a covariate in the model. Interaction between treatment group and sex was found in the following end points: All- cause death (P < .001); any revascularization (P = .022); target-lesion revascularization (P=.004); target-vessel revascularization (P = .010).
    [Show full text]
  • A Nonsynonymous Functional Variant of the ITGAM Gene Is Not Involved in Biopsy-Proven Giant Cell Arteritis F
    A Nonsynonymous Functional Variant of the ITGAM Gene Is Not Involved in Biopsy-proven Giant Cell Arteritis F. DAVID CARMONA, AURORA SERRANO, LUIS RODRÍGUEZ-RODRÍGUEZ, SANTOS CASTAÑEDA, JOSÉ A. MIRANDA-FILLOY, INMACULADA C. MORADO, JAVIER NARVÁEZ, ROSER SOLANS, BERNARDO SOPEÑA, BEGOÑA MARÍ-ALFONSO, AINHOA UNZURRUNZAGA, NORBERTO ORTEGO-CENTENO, RICARDO BLANCO, EUGENIO DE MIGUEL, ANA HIDALGO-CONDE, JAVIER MARTÍN, and MIGUEL A. GONZÁLEZ-GAY ABSTRACT. Objective. To investigate whether a functional integrin alpha M (ITGAM) variant is involved in sus- ceptibility to and clinical manifestations of giant cell arteritis (GCA). Methods. A Spanish cohort of 437 white patients with biopsy-proven GCA and 1388 healthy controls were genotyped using the TaqMan allele discrimination technology. Results. No association was observed between ITGAM rs1143679 and GCA (p = 0.80, OR 0.97). Similarly, subphenotype analyses did not yield significant differences between the case subgroups and the control set or between GCA patients with or without the main specific features of GCA. Conclusion. Our results suggest that the ITGAM rs1143679 variant does not play an important role in the pathophysiology of GCA. (First Release Oct 1 2011; J Rheumatol 2011;38:2598–601; doi:10.3899/ jrheum.110685) Key Indexing Terms: GIANT CELL ARTERITIS TEMPORAL ARTERITIS SINGLE-NUCLEOTIDE POLYMORPHISM ITGAM rs1143679 Integrin alpha M (ITGAM) encodes the alpha subunit of the and the most likely causal polymorphism within the ITGAM αMß2-integrin. A nonsynonymous single-nucleotide poly- region in several populations of different ethnicity1,2. There is morphism (SNP) at exon 3 of the ITGAM gene, rs1143679, evidence suggesting that ITGAM rs1143679 is also involved produces a functional modification in the protein by changing in the pathogenesis of systemic sclerosis (SSc)3.
    [Show full text]
  • Aerospace Services Content
    AEROSPACE SERVICES CONTENT NON-DESTRUCTIVE TESTING 2 METROLOGY AND CALIBRATION 3 OIL AND FUEL LABORATORIES 4 CERTIFICATION 5 ENVIRONMENT 6 AIRPORT 7 SUPPLY CHAIN INSPECTION AND TECHNICAL ASSITANCE 8 CE MARKING 9 EMC TESTING 10 GLOBAL REACH WHO ARE SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 95,000 em- WE? ployees, SGS operates a network of over 2,400 offices and laboratories around the world. INDSUTRY EXPERTISE Our NDT division has more than 200 NDT technicians (levels II and III) who are highly qualified to provide the highest level of service and expertise. SGS, as an EASA 145 aircraft maintenance center, has the experience and capabilities to satisfy a wide variety of customers needs within the aerospace sector. Other approvals, including NADCAP, are evidence of our high performance and experience in the industry, with clients such as EADS, Airbus, R&R and more. CONTACT: To speak to our North American aerospace team, use the contact information below. +1 844 730 4175 (toll-free) [email protected] 1 NON-DESTRUCTIVE TESTING SGS is the world’s leading inspection services company, providing: BENEFITS • Experience and knowledge in aeronautical maintenance and the manufacturing Our comprehensive range of NDT industry methods can help you to: • Availability of human and material resources • Detect defects and irregularities • Localized service in aviation parts and assets before they result in damage or SGS boasts several accreditations specific to the aeronautical sector, including: non-compliance • Ensure safe and reliable operation of your fleet or • NADCAP aerospace products • EASA Part 145 • Gain NDT services and composite inspection during fabrication • CESSNA AUTHORIZED INDEPENDENT NDI FACILITY in different sites, under our NADCAP approval NON-DESTRUCTIVE TESTING TAILORED TO THE AVIATION INDUSTRY We offer the most effective NDT methods tailored to the aviation industry.
    [Show full text]